维生素E对儿科代谢功能障碍相关的脂肪性肝病中的心脏代谢因子的影响:通过元分析进行系统性审查
Pedram Pam1,2,3, Vali Musazadeh4,5, Mahsa Mahmoudinezhad1,2,3
1Food and Beverages Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran.
The British journal of nutrition
|November 6, 2025
概括
维生素E补充剂改善了患有代谢功能障碍相关脂肪性肝病 (MASLD) 的儿童的ALT和AST等肝酶. 它还对总胆固醇和胰岛素耐药性产生了积极的影响,这表明它可能具有辅助治疗作用.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 儿科胃肠病学 儿科胃肠病学
- 营养科学 营养科学
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是儿童日益严重的健康问题.
- MASLD与2型糖尿病和心血管疾病 (CVD) 等严重疾病有关.
- 维生素E是一种强大的抗氧化剂,因其改善肝脏和心脏代谢健康的潜力而受到研究.
研究的目的:
- 评估维生素E补充剂在儿科MASLD中的疗效.
- 评估维生素E对肝酶,脂质概况,血糖控制和人类测量的影响.
- 确定维生素E作为儿科MASLD潜在辅助疗法的作用.
主要方法:
- 进行了全面的文献搜索,截至2025年3月.
- 使用随机效应模型分析了11项涉及665名参与者的随机对照试验.
- 提取的数据包括肝酶 (ALT,AST,GGT),血糖指数 (FBS,胰岛素,HOMA-IR),脂质资料 (TC,TAG,LDL-C,HDL-C) 和维生素E水平.
主要成果:
- 维生素E显著降低了阿兰氨基转移酶 (ALT) 和酸氨基转移酶 (AST) 的水平.
- 总胆固醇 (TC) 和胰岛素耐药性 (HOMA-IR) 的同静态模型评估显著下降.
- 血清维生素E水平显著增加,而BMI,GGT,FBS,胰岛素,LDL-C,HDL-C和TAG没有显著变化.
结论:
- 维生素E补充剂在改善儿科MASLD中的肝酶标记物 (ALT,AST) 方面显示出有前途.
- 它有利地影响代谢因素,如总胆固醇和胰岛素抵抗 (HOMA-IR).
- 维生素E可以作为诊断为MASLD的儿童有益的辅助疗法.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
157
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
157
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
165
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
165
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
179
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
179
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
193
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
193
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
01:28Overview of Fatty Acid Metabolism
36.1K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
36.1K